Angiogenesis meets immunology: Cytokine gene therapy of cancer

摘要: Abstract Delivery of cytokine genes at the tumor site in pre-clinical models has been shown to recruit host inflammatory cells followed by inhibition growth. This local effect is often accompanied systemic protection mediated immune system, mainly CD8 + T and NK cells. On this basis, gene-transduced have widely used as vaccines clinical trials, which good safety profiles some responses but substantial lack efficacy. Are these findings end story? Possibly not, if major improvements will be attained coming years. These should directed level gene selection delivery, order identify optimal achieve efficient durable expression, improving stimulation, i.e. co-administration co-stimulatory molecules including B7 CD40, or boosting expression antigens MHC class I molecules. Interestingly, cytokines encouraging anti-tumor activity, IFNs, IL-4, IL-12 TNF-α, are endowed with anti-angiogenic vasculotoxic effects, may significantly contribute control. Therapeutic exploitation property result design novel approaches which, maximizing immune-stimulating could possibly lead starvation established tumors patients.